Curated News
By: NewsRamp Editorial Staff
November 19, 2025
Quantumzyme to Showcase Sustainable Enzyme Tech at CCE-2026
TLDR
- Quantumzyme's enzyme engineering platform offers pharmaceutical manufacturers competitive advantages through cost-efficient production and sustainable API manufacturing pathways.
- Quantumzyme uses computational enzyme engineering and biocatalytic routes to reduce waste, lower carbon intensity, and improve process reliability in pharmaceutical manufacturing.
- Quantumzyme's sustainable enzyme technology supports cleaner pharmaceutical production, reducing environmental impact and advancing global sustainability goals for future generations.
- Quantumzyme is showcasing innovative enzyme engineering for green ibuprofen synthesis and chiral molecule production at the CCE-2026 conference in Boston.
Impact - Why it Matters
This development matters because it addresses critical challenges in pharmaceutical manufacturing that affect both environmental sustainability and supply chain security. Traditional chemical synthesis methods for pharmaceuticals generate substantial waste, consume high amounts of solvents, and contribute significantly to carbon emissions. Quantumzyme's enzyme engineering platform offers a transformative approach that could substantially reduce the environmental footprint of drug manufacturing while making production more cost-effective. Furthermore, as global concerns grow about pharmaceutical supply chain vulnerabilities and the need for domestic manufacturing capacity, this technology supports U.S. onshoring initiatives for essential medicines. The advancement in green ibuprofen synthesis specifically demonstrates how everyday medications could become more sustainable and affordable, potentially lowering healthcare costs while reducing environmental impact. For pharmaceutical companies, this represents an opportunity to meet growing regulatory and consumer demands for greener manufacturing practices without sacrificing efficiency or profitability.
Summary
Quantumzyme Corp., a global leader in computational enzyme engineering, has announced its participation in the Catalysis and Chemical Engineering Conference (CCE-2026) scheduled for March 9-11, 2026, in Boston, MA. The company will showcase how its innovative enzyme engineering platform is transforming traditional chemical synthesis methods and enabling more sustainable, cost-efficient pathways for pharmaceutical manufacturing. This participation reflects Quantumzyme's expanding role in advancing green chemistry solutions for the biomanufacturing sector, particularly as global demand grows for low-waste, energy-efficient pharmaceutical production methods.
At the conference, Quantumzyme will highlight significant advancements in green ibuprofen synthesis, featuring biocatalytic routes that substantially reduce environmental impact and manufacturing costs. The company will also present the ongoing expansion of its enzyme engineering platform to high-volume Active Pharmaceutical Ingredients (APIs), including new applications in chiral molecule synthesis supported by next-generation ketoreductase (KRED) enzymes. These developments demonstrate Quantumzyme's continued progress in delivering practical, scalable solutions that support cleaner and more efficient pharmaceutical production. Throughout CCE-2026, the company plans to engage with researchers, pharmaceutical manufacturers, process development teams, technology developers, and investors focused on green chemistry and biomanufacturing to explore partnerships that could accelerate the adoption of enzyme-based manufacturing approaches.
Quantumzyme's technology aligns with global sustainability and decarbonization goals, as well as U.S. initiatives to strengthen domestic API manufacturing capacity. The platform specifically addresses challenges in current API production, which often depends on legacy chemistries that generate significant waste and require high solvent usage. By enabling greener, more reliable, and locally scalable biocatalytic pathways, Quantumzyme's platform aims to reduce waste and solvent consumption, lower carbon intensity in API production, improve process reliability and consistency, and support U.S. onshoring and supply-chain resilience for essential medicines. For more information, interested parties can visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM, as well as view the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Quantumzyme to Showcase Sustainable Enzyme Tech at CCE-2026
